Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Author:
Funder
AIRC
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Link
http://link.springer.com/content/pdf/10.1186/s12943-018-0805-1.pdf
Reference139 articles.
1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.
2. Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep. 2013;8:71–80.
3. Fabio Stagno SS, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Rev Anticancer Ther. 2016;16:273–8.
4. Tessa L, Holyoake GVH. Do we need more drugs for chronic myeloid leukemia? Immunol Rev. 2015;263:106–23.
5. Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirro E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, et al. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis. 2014;35:1132–43.
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review;Biomarkers in Medicine;2023-12
2. Talaromyces marneffei suppresses macrophage inflammation by regulating host alternative splicing;Communications Biology;2023-10-16
3. Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression;Current Molecular Pharmacology;2023-08
4. Designing temporal- and spatial-control multifunctional nanoformulations for synergistic photodynamic–enhanced tumour immunotherapy;Nano Today;2023-04
5. In the Pipeline: Emerging Therapy for CML;Pathogenesis and Treatment of Leukemia;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3